Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.69 |
| ▸ | HTT | P42858 | 6/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.57 |
| ▸ | CTSD | P07339 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2575692 | 0.90 | CTSD (0.58) | KDM4EALDH1A1HTTHPGDSMN1; SMN2 | |
| SCHEMBL2582149 | 0.84 | TSHR (0.57) | KDM4EALDH1A1HTTHPGDSMN1; SMN2 | |
| SCHEMBL2578815 | 0.84 | CTSD (0.51) | KDM4EALDH1A1HTTHPGDSMN1; SMN2 | |
| SCHEMBL1385523 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1HTTSMN1; SMN2MAPT | |
| SCHEMBL1384956 | 0.83 | ALDH1A1 (0.56) | KDM4EALDH1A1HTTHPGDSMN1; SMN2 | |
| SCHEMBL2583244 | 0.82 | CTSD (0.58) | KDM4EALDH1A1SMN1; SMN2MAPTTSHR | |
| SCHEMBL20887162 | 0.80 | KDM4E (0.88) | KDM4EALDH1A1HTTHPGDSMN1; SMN2 | |
| SCHEMBL1160486 | 0.80 | KDM4E (0.58) | KDM4EALDH1A1HTTHPGDSMN1; SMN2 | |
| SCHEMBL2582550 | 0.80 | ALDH1A1 (0.64) | KDM4EALDH1A1HTTHPGDSMN1; SMN2 | |
| SCHEMBL5037413 | 0.79 | KDM4E (0.62) | KDM4EALDH1A1HTTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636215-B1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2008-01-23 | — | — | EP | claimed |
| US-10724072-B2 | Use of phospho-Akt as a biomarker of drug response | BASILEA PHARMACEUTICA AG (CH) | 2020-07-28 | — | — | US | disclosed |
| US-10656162-B2 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2020-05-19 | — | — | US | disclosed |
| US-10222377-B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2019-03-05 | — | — | US | disclosed |
| US-20190010536-A1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | BASILEA PHARMACEUTICA AG (CH) | 2019-01-10 | — | — | US | disclosed |
| US-20180364254-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG | 2018-12-20 | — | — | US | disclosed |
| US-10067120-B2 | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2018-09-04 | — | — | US | disclosed |
| US-10006078-B2 | Use of phospho-Akt as a biomarker of drug response | BASILEA PHARMACEUTICA AG (CH) | 2018-06-26 | — | — | US | disclosed |
| US-9995754-B2 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2018-06-12 | — | — | US | disclosed |
| US-9970938-B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2018-05-15 | — | — | US | disclosed |
| WO-2012113802-A1 | USE OF ACETYLATED TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012098207-A1 | USE OF BUBR1 AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098208-A1 | USE OF STATHMIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098203-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-RE42890-E1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-7385061-B2 | 4-[1-(6-amino-3-pyridylcarbonylmethyl)-1H-benzimidazol-2-yl]-furazan-3-yl]-N-(2-cyanoethyl)-amine; treatment of neoplastic and autoimmune diseases | BASILEA PHARMACEUTICA AG (CH) | 2008-06-10 | — | — | US | disclosed |
| EP-1636215-B1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-20070043061-A1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG | 2007-02-22 | — | — | US | disclosed |
| EP-1636215-A1 | FURAZANOBENZIMIDAZOLES | Basilea Pharmaceutica AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004103994-A1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10724072-B2 | Use of phospho-Akt as a biomarker of drug response | AKT3, AKT1S1, AKT2 | KDM4E 3884/4885ALDH1A1 4829/4885HTT 3440/4885 |
| US-10656162-B2 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | TUBB, TUBB1, TUBB6 | KDM4E 4206/4885ALDH1A1 1153/4885HTT 2608/4885 |
| US-20180364254-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | TUBB, TUBB1, TUBB6 | KDM4E 4206/4885ALDH1A1 1153/4885HTT 2608/4885 |
| US-20190010536-A1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | AKT3, AKT1S1, AKT2 | KDM4E 3884/4885ALDH1A1 4829/4885HTT 3440/4885 |
| US-10067120-B2 | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles | TUBB1, TUBB, TUBB6 | KDM4E 3837/4885ALDH1A1 595/4885HTT 2770/4885 |
| US-10222377-B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | BUB1B, BUB1, BUB3 | KDM4E 2211/4885ALDH1A1 1640/4885HTT 4803/4885 |
| US-10006078-B2 | Use of phospho-Akt as a biomarker of drug response | AKT3, AKT2, AKT1S1 | KDM4E 4613/4885ALDH1A1 4762/4885HTT 3335/4885 |
| US-20070043061-A1 | Furazanobenzimidazoles | FOXO1, CYP2F1, OXER1 | KDM4E 1039/4885ALDH1A1 335/4885HTT 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.